Generated by All in One SEO v4.9.5.1, this is an llms.txt file, used by LLMs to index the site.

# HUB Organoids

## Sitemaps

- [XML Sitemap](https://www.huborganoids.nl/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Patient-derived organoids CRO | Drug discovery | Organoid development services](https://www.huborganoids.nl/) - A PATIENT IN THE LAB® HUB Organoids predict patient response to treatment. Our patented technology allows the development of patient-derived “mini-organs in a dish” from both healthy and diseased tissues to close the gap between the lab and the clinic.
- [Meet Us](https://www.huborganoids.nl/meet-us/)
- [Antibody-Drug-Conjugate Solutions | ADC | Organoid Technology](https://www.huborganoids.nl/antibody-drug-conjugate-organoid-solutions/) - Test efficacy & safety, access tumor antigen expression, discover biomarkers of response. Learn about Antibody-Drug-Conjugate Solutions with Organoid Technology
- [Patient-derived organoids for preclinical toxicology](https://www.huborganoids.nl/toxicology/) - THE CHALLENGE About 30% of drugs fail human trials because of toxicity, even after passing animal-based preclinical safety tests The current drug development process is inefficient, costly, and risky. An analysis of 221 animal studies showed that their outcomes matched subsequent human trials only half the time. Furthermore, animal tests do not accurately forecast toxicity
- [PDO Monolayer | Physiologically-relevant solutions for Inflammatory bowel disease | Intestinal organoid](https://www.huborganoids.nl/services-hub-drug-screening-inflammatory-diseases-pdo-monolayer) - Brought to you by the scientists who developed the first gut organoid! Development of the first ever human intestinal organoid Establishment of PDO monolayer platform Characterization of the IBD organoid biobank for commercial screening IntegriGut Screen extends reach with worldwide launch PDO Monolayer Addressing unmet medical needs with innovative solutions Recognizing the significant challenge in
- [Careers](https://www.huborganoids.nl/careers/) - What we offer We are a science driven company with an unwavering commitment to apply HUB Organoid Technology globally to provide patient benefit. At HUB, everyone is encouraged to develop their personal capabilities, innovate, embrace challenges, and strive for the excellence in everything we do. HUB offers its employees a unique position to be part
- [Metastatic Colorectal Cancer Drug Screening with Patient-Derived Organoids](https://www.huborganoids.nl/metastatic-colorectal-cancer-drug-screening-with-patient-derived-organoids)
- [HUB Drug Screening Services | Patient-Derived Organoid Solutions](https://www.huborganoids.nl/services/drug-screening-solutions) - Explore HUB Organoids Drug Screening Services: Predict patient responses with patient-derived organoid solutions for oncology, toxicology, inflammation, and more.
- [PDO Screen | Patient-derived organoid screen | Accelerate Oncology Research](https://www.huborganoids.nl/pdo-screen-drug-testing/) - Jumpstart your project with ongoing organoid screens Colorectal cancer book your screen Bladder cancer book your screen KRASpanel book your screen ATP-based cell-viability assay, with IC50 readouts 3D assay format, compatible with both 96- and 384-well plate layouts. Test up to 10 compounds in triplicate 10-point dose-response curves per drug Preset organoid panel with key
- [Organoid Toxicology case study: How we helped our client anticipate on- and off-target toxicity using patient-derived organoids](https://www.huborganoids.nl/toxicology/target-toxicity-using-patient-derived-organoids/)
- [Apply for a license LP](https://www.huborganoids.nl/apply-for-a-license-lp/) - Ready to take the next step? Need more guidance? book a consultation Are you an academic interested in purchasing HUB Organoids from our biobank to perform basic research in your laboratory? Now you can directly request organoids here. Open Modal
- [About HUB](https://www.huborganoids.nl/about/) - Our story 2009 First organoid generated from mouse intestine 2011 First human organoid developed from intestinal epithelium 2013 Hubrecht Organoid Technology Foundation was established to upscale and commercialize organoid technology 2015 First cystic fibrosis patient treated based on organoid data 2017 HIT-CF validation trial launched 2018 First oncology clinical candidate entirely developed using organoid screening
- [Organoids Podcasts](https://www.huborganoids.nl/resources/podcasts) - Explore our episodes: Featuring leading research on patient-derived organoids and their growing power to transform drug development and personalise medical care
- [Podcast Episode 3: Organoid Platforms for Drug Discovery and Safety](https://www.huborganoids.nl/podcast-organoid-platforms-for-drug-discovery-and-safety) - For full experimental and analytical details, read the research paper view publication Stay updated on the latest in organoid science — get new podcast episodes delivered straight to your inbox
- [Podcast Episode 2: Modelling colorectal cancer progression in a dish](https://www.huborganoids.nl/podcast-modelling-colorectal-cancer-progression-in-a-dish) - For full experimental and analytical details, read the research paper view publication Stay updated on the latest in organoid science — get new podcast episodes delivered straight to your inbox
- [License HUB Organoid Technology](https://www.huborganoids.nl/licenses/) - HUB Organoid Technology represents a breakthrough in the field of stem cell research and it is based on extensive knowledge of the underlying biology of adult stem cells. A license is required when our industry partners wish to use HUB’s proprietary Organoid Technology in-house. We offer license packages to companies that pursue the technology for
- [Podcast Episode 1: Discovery of adult-stem cell derived organoids](https://www.huborganoids.nl/podcast-discovery-of-adult-stem-cell-derived-organoids) - For full experimental and analytical details, read the research paper view publication Stay updated on the latest in organoid science — get new podcast episodes delivered straight to your inbox
- [Challenges in Drug Development: Fail Fast, Capital Efficiency Strategy & Portfolio Optimization with HUB Organoids](https://www.huborganoids.nl/challenges-in-drug-development) - THE CHALLENGE Late-stage clinical failure is the single largest driver of R&D waste. Clinical trials consume the majority of sunk capital, leaving companies exposed to multi-hundred-million dollar write-offs when late candidates fail. In traditional drug development, only about 1 in 10 programs successfully reaches approval. This means the cost of all failed candidates is effectively
- [HUB Organoid Technology | Patient-Derived Organoids for Drug Discovery](https://www.huborganoids.nl/hub-organoid-technology/) - Explore HUB Organoid Technology: Patient-derived organoids for drug discovery, disease modeling, and predictive therapeutic insights
- [Patient-derived organoids of Inflammatory diseases | IBD | organoid co-culture](https://www.huborganoids.nl/services/hub-drug-screening-inflammatory-diseases) - Advance IBD preclinical drug development with confidence with patient-derived organoids monolayers and organoids and immune cells co-cultures.
- [How we supported our client in advancing biomarker discovery and translational ADC development](https://www.huborganoids.nl/case-study-adc-screening-solutions)
- [Patient-Derived Organoid Services | Drug Screening & Assay Development](https://www.huborganoids.nl/services) - Explore HUB Organoids' services: drug screening, custom assay development, and clinical trials in a dish. Empower your drug development today
- [Model Dev DD](https://www.huborganoids.nl/model-dev)
- [Patient-derived organoids of Infectious Diseases | Organoids CRO](https://www.huborganoids.nl/services/hub-drug-screening-infectious-disease) - THE CHALLENGE When potency varies 100-fold between animal & cell lines, how confident can you be in your hit list? Many antivirals, antibacterials or host-directed therapeutics fail in translation because they are evaluated in cell lines or animal models that do not recapitulate human tissue complexity, cell types, polarization, or multi-cell context. These models often Advance infectious disease preclinical drug development with patient-derived organoids monolayers and bacterial or viral co-cultures
- [Organoid Toxicology case study: How organoid data guided our client in selecting a human-relevant animal model for preclinical toxicology studies](https://www.huborganoids.nl/toxicology/make-educated-selection-animal-models/)
- [Organoid Toxicology Case Study : How we supported our client translate animal toxicity data to human-relevant insights and identify a therapeutic window](https://www.huborganoids.nl/toxicology/toxicology-case-study-make-sense-of-animal-data-with-human-organoids/)
- [How we enabled our client to assess efficacy and selectivity of a bispecific antibody using organoid-based co-cultures](https://www.huborganoids.nl/case-study-bispecifics)
- [How we modelled human fibroblast-epithelial interactions with organoids to identify IBD targets](https://www.huborganoids.nl/ibd/organoid-fibroblast-co-culture-case-study) - Discover our IBD case study using patient-derived organoids co-cultures, modelling fibroblast-epithelial interactions for drug discovery.
- [Immuno-Oncology](https://www.huborganoids.nl/services/immuno-oncology-patient-derived-organoids) - THE CHALLENGE Up to 88% of immunotherapies fail after Phase I trials Despite recent clinical successes, the path to approval remains steep for immuno-oncology candidates. Immunotherapies exhibit an overall likelihood of approval of 12.4%, significantly higher than other oncology drugs (5.3%), but still reflect a high failure rate. Most notably, Phase II is the biggest
- [Organoids in Oncology Drug Development | Services](https://www.huborganoids.nl/services-organoids-in-cancer-research) - AN INEFFECTIVE LINEAR PIPELINE Only 5% of drugs showing preclinical efficacy progress beyond Phase III oncology trials The current oncology drug development process is fundamentally flawed. It adheres to a linear methodology that predominantly depends on cancer cell lines and animal models. These traditional models, however, fail to replicate the intricate and heterogeneous nature of
- [Organoid-based Solutions for KRAS Inhibitor Testing](https://www.huborganoids.nl/kras-inhibitor-testing-organoid-solutions/) - Accelerate KRAS-targeted drug discovery with HUB Organoids' patient-derived models. Explore predictive screens, resistance models, and a diverse PDO biobank."
- [Case Study: Preclinical Drug Development](https://www.huborganoids.nl/oncology/case-study-preclinical-drug-development/)
- [Oncology](https://www.huborganoids.nl/oncology/) - Coming soon
- [<span>HUB</span> News](https://www.huborganoids.nl/news-insights-2/)
- [Privacy Policy](https://www.huborganoids.nl/privacy-policy/) - 1. Important notice For the purposes of relevant data protection legislation, we are a controller of your personal data and as a controller we use the personal data we hold about you in accordance with this Privacy Notice. This is the Privacy and Cookie Notice of the website of HUB Organoids B.V. hereafter: (‘Website’). This
- [Organoids in Oncology Drug Development | BACKUP](https://www.huborganoids.nl/organoids-in-oncology-drug-development-backup/) - AN INEFFECTIVE LINEAR PIPELINE Only 5% of drugs showing preclinical efficacy progress beyond Phase III oncology trials The current oncology drug development process is fundamentally flawed. It adheres to a linear methodology that predominantly depends on cancer cell lines and animal models. These traditional models, however, fail to replicate the intricate and heterogeneous nature of
- [PDO Screen | Patient-derived organoid screen | Accelerate Oncology Research](https://www.huborganoids.nl/pdo-screen-test/) - Jumpstart your project with ongoing organoid screens Colorectal cancer book your screen Bladder cancer book your screen KRASpanel book your screen ATP-based cell-viability assay, with GR50 readouts 3D assay format, compatible with both 96- and 384-well plate layouts. Test up to 10 compounds in triplicate 10-point dose-response curves per drug Preset organoid panel with key
- [Home](https://www.huborganoids.nl/home-2/) - A PATIENT IN THE LAB® HUB Organoids predict patient response to treatment. Our patented technology allows the development of patient-derived “mini-organs in a dish” from both healthy and diseased tissues to close the gap between the lab and the clinic.
- [Patient-derived organoid based drug development services](https://www.huborganoids.nl/services-overview/)
- [Oncology | Patient-derived organoid screen | bladder cancer](https://www.huborganoids.nl/pdo-screen-bladder-cancer-organoids-2023/) - Key features of our bladder cancer PDO panel A comprehensive collection of 10 bladder cancer PDOs, sourced from both treatment-naïve and pre-treated patients Rigorously characterized, with readily available DNA and RNA sequencing data Diverse models encompassing both non-invasive and advanced muscle-invasive bladder cancer Benchmarked against standard-of-care (SoC) treatments such as Erdafitinib and Gemcitabine Representing pivotal
- [HUB Organoids | Clinical Trial in a Dish | predict patient response in the clinic](https://www.huborganoids.nl/hub-organoid-clinical-trial-in-a-dish/)
- [New patient-derived organoid model and assay development](https://www.huborganoids.nl/model-and-assay-development/)
- [EXCLUSIVE YEAR END OFFER](https://www.huborganoids.nl/exclusive-year-end-offer/)
- [Apply for a license LP TEST](https://www.huborganoids.nl/apply-for-a-license-lp-test/) - Ready to take the next step? Need more guidance? book a consultation Are you an academic interested in purchasing HUB Organoids from our biobank to perform basic research in your laboratory? Now you can directly request organoids here. Open Modal
- [New Popup](https://www.huborganoids.nl/new-popup/) - XHUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Companyread more
- [Model and Assay Development (OLD)](https://www.huborganoids.nl/model-and-assay-development-old/) - Innovate with us: novel disease models With our mission to increase the global accessibility of adult stem cell-derived organoids, we highly support research collaborations catered to the development of novel disease models in therapeutic areas of high unmet need. Work with us to use our state-of-the-art technology and extensive expertise to develop new clinically relevant
- [HUB Drug Screening (OLD)](https://www.huborganoids.nl/screening-organoid-assay-services-hub-organoids/hub-drug-screening-old/)
- [Custom Solutions](https://www.huborganoids.nl/custom-solutions/)
- [HUB Organoid Clinical Trial in a Dish](https://www.huborganoids.nl/screening-organoid-assay-services-hub-organoids/hub-organoid-clinical-trial-in-a-dish-old/) - Clinical Trials in a Dish (CTiD) HUB Organoids can support clinical trials in "co-clinical" applications whereby organoids are developed from patient biopsies while they are enrolled in a clinical trial (Phase I to III). In this settings HUB Organoids are treated similarly to patients in the clinic to: prospectively identify responders and non-responders in subsequent
- [Animation Test](https://www.huborganoids.nl/careers/test/)
- [Custom Solutions Workflow](https://www.huborganoids.nl/custom-solutions-workflow/)
- [Contact](https://www.huborganoids.nl/contact/) - Get in touch Tell us a bit more about you so we can best assist Call us directly +31 (0)88 12 36 300 Chat with us Use our chatbot to learn more General enquiries Send us an email Contact us
- [License HUB Organoid Technology](https://www.huborganoids.nl/screening-organoid-assay-services-hub-organoids/license-hub-organoid-technology/) - Forskolin-Induced Swelling Assay The Forskolin-Induced Swelling (FIS) assay is an imaging-based assay that measures organoid swelling as a readout for Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein function before and after treatment to provide indications on a new drug efficacy and patient response. The FIS assay is a valuable tool in Cystic Fibrosis (CF) drug
- [Advance your immunotherapy drug development with patient-derived organoids](https://www.huborganoids.nl/patient-derived-organoids-co-cultures-immuno-oncology/) - Validate your immunotherapeutic with the pioneers of adult stem cell-derived organoid technology Leverage the capabilities of our organoid-based drug screening platform and a wide range of established assays to access the efficacy, potency, and toxicity of your immunotherapy. We have successfully led the development of: Bispecific antibodies Engineered T cells CAR-T cells Antibody-drug conjugates (ADC)
- [Home - DEV](https://www.huborganoids.nl/home-dev/) - A PATIENT IN THE LAB® HUB Organoids predict patient response to treatment. Our technology allows the development of patient-derived “mini-organs in a dish” from both healthy and diseased tissues to close the gap between the lab and the clinic.
- [Home Animated Canvas Test](https://www.huborganoids.nl/home-animated-canvas-test/)
- [Transepithelial Electrical Resistance Teer Assay](https://www.huborganoids.nl/transepithelial-electrical-resistance-teer-assay/) - Quick facts Assay layout: 24- and 96-well plate format Read out: measurement of fluorescence (permeability/barrier function) and cellular ATP levels (cell viability) Application area: epithelial biology, barrier disfunction (IBD, celiac disease, leaky gut), toxicology
- [Partnering Opportunities](https://www.huborganoids.nl/partnering/) - Licensing To foster HUB Organoid™ adoption, we offer various licensing opportunities to our proprietary HUB Organoid Technology which cover different research fields and various purposes of use. Our licenses include a technology transfer package, dedicated on-site training, and access to our biobank to help you implement our knowhow in-house. apply for a license
- [Immune-mediated Tumor organoid Killing Assay](https://www.huborganoids.nl/immune-mediated-tumor-cell-killing-assay/) - Quick facts Assay layout: 96-well plate format Read out: organoid cell death and/or IFNγ production Application area: immuno-oncology
- [Custom Registration Page: Subscribers](https://www.huborganoids.nl/register/) - Already have an account? Login here.
- [Custom Login Page: Subscribers](https://www.huborganoids.nl/login/)
- [Cell Viability and Cytotoxicity Assay](https://www.huborganoids.nl/cell-viability-and-cytotoxicity-assay/) - Quick facts Assay layout: 96- and 384-well plate format Read out: measurement of cellular ATP levels Application area: oncology, toxicology, IBD, COPD
- [Forskolin-induced Swelling (FIS) Assay](https://www.huborganoids.nl/forskolin-induced-swelling-fis-assay/) - Quick facts Assay layout: 96-well plate format Read out: quantification of organoid forskolin-induced swelling (FIS) Application area: CF

## News

- [The Life Science business of Merck KGaA, Darmstadt, Germany Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio](https://www.huborganoids.nl/news/the-life-science-business-of-merck-kgaa-darmstadt-germany-acquires-hub-organoids-holding-bv-expands-next-gen-biology-portfolio/) - Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio of media, reagents, and benchtop instrumentation Organoids provide drug response data earlier in the development process while helping to maintain project scale Darmstadt, Germany, January 6, 2025 – The Life Science business of
- [The Life Science business of Merck KGaA, Darmstadt, Germany, to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio](https://www.huborganoids.nl/news/merck-to-acquire-hub-organoids-holding-bv-advancing-next-generation-biology-portfolio/) - HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organoids part of fastest growing cell culture segment; hold potential to speed up drug development, reduce animal testing Darmstadt, Germany, December 17, 2024 – The Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company,
- [HUB Organoids B.V. Awarded Frost & Sullivan's 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology](https://www.huborganoids.nl/news/hub-organoids-b-v-awarded-frost-sullivans-2024-technology-innovation-leadership-award-for-transforming-drug-development-with-highly-advanced-organoid-technology/) - HUB Organoids B.V. revolutionizes preclinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency. San Antonio, TX — May 14 2024 — Frost & Sullivan recently researched the organoids landscape and, based on its findings, recognizes HUB Organoids B.V (HUB) with the 2024 Global Technology Innovation Leadership Award. HUB is a
- [HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD)  Drug Discovery and Development](https://www.huborganoids.nl/news/integrigut-screen-launch-for-inflammatory-bowel-disease/) - Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology for drug discovery and development, today announced the global launch of its new IntegriGut Screen. This innovative screening service employs IBD patient-derived organoid monolayers (PDO Monolayers) allowing access to high-quality human data on epithelial barrier
- [Tumors in Space Investigates Microgravity's Impact on Cancer Using Patient-Derived HUB Organoids](https://www.huborganoids.nl/news/tumors-in-space-hub-organoids-for-cancer-research/) - Utrecht, November 30, 2023 – HUB Organoids B.V. participates in the second Tumors in Space European Space Agency parabolic flight which investigates the effect of microgravity on gene expression to identify potential targets for drug discovery and precision medicine. The Tumors in Space program represents some of the most advanced cancer research ever conducted under
- [HUB Organoids take their first parabolic flight!](https://www.huborganoids.nl/news/hub-organoids-take-their-first-parabolic-flight/)
- [HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company](https://www.huborganoids.nl/news/hub-organoids-announces-new-corporate-strategy-and-completes-transition-from-foundation-to-private-company/) - [Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a significant milestone in its evolution. After years of successful operations as a foundation, HUB has transitioned to a private company structure. This corporate structure reflects HUB's commitment to innovation, customer-focus, growth, and strategic
- [HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology](https://www.huborganoids.nl/news/hub-organoids-extends-partnership-with-molecular-devices-to-advance-automated-intestinal-organoid-screening-technology/) - SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and HUB Organoids (HUB), the pioneer in the field of adult stem cell-derived organoids, today announced a strategic collaboration enabling continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to
- [FDA Modernization Act 2.0:  We welcome the dawn of an organoid era](https://www.huborganoids.nl/news/fda-modernization-act-2-0-we-welcome-the-dawn-of-an-organoid-era/)
- [HUB Organoids and Yamaha Motor announce their collaboration combining their proprietary technologies](https://www.huborganoids.nl/news/hub-and-yamaha-motor-announce-their-collaboration-combining-their-proprietary-technologies/) - February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their collaboration to provide solutions that deepen our understanding in predictive diagnostic of patients. HUB has announced an innovative collaboration with Yamaha Motor to support organoid research applications in drug development and personalised medicine. With this collaboration, HUB aims
- [HUB Organoid Technology and Crown Bioscience announce strategic partnership](https://www.huborganoids.nl/news/hubrecht-organoid-technology-and-crown-bioscience-announce-strategic-partnership/) - March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation, the parent company, of Crown Bioscience, entered into a strategic partnership to provide preclinical oncology drug development and validation services using HUB Organoid Technology. As part of the agreement CrownBio, a wholly–owned subsidiary of JSR Corporation will expand its European presence by opening a
- [HUB Patient-Derived Organoids added to CrownBio`s unique Platform designed to disrupt traditional Drug Discovery workflows](https://www.huborganoids.nl/news/hub-patient-derived-organoids-added-to-crownbio-s-unique-platform-designed-to-disrupt-traditional-drug-discovery-workflows/) - San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology (HUB) patient-derived organoids (PDO). This marks a significant milestone in the development of CrownBio’s innovative organoid platform and the first, large-scale commercial availability of HUB PDO for oncology drug discovery services. Organoid technologies
- [Epistem license HUB Organoid Technology to expand preclinical toxicology service portfolio](https://www.huborganoids.nl/news/epistem-license-hubrecht-organoid-technology-to-expand-preclinical-toxicology-service-portfolio/) - Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification
- [HUB and MIMETAS to develop and market "organoids-on-a-chip"](https://www.huborganoids.nl/news/hub-and-mimetas-to-develop-and-market-organoids-on-a-chip/) - Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to market organoid models on a chip. The agreement includes a license to MIMETAS to market HUB Organoids™ in an assay ready format, as well as a collaborative effort to develop disease-specific models. “We’re delighted and
- [New PDX-derived organoid platform for oncology drug development launched at CrownBio](https://www.huborganoids.nl/news/new-patient-derived-tumor-organoid-drug-development-platform-launched-at-crownbio/) - San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery. The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models generated from CrownBio’s uniquely-characterized
- [Financial Times interviews Prof. Clevers about HUB](https://www.huborganoids.nl/news/hub-organoids-featured-by-the-financial-times/) - On December 10, 2019 the Financial Times featured HUB Organoids™ in an article titled “Organoid innovation offers potential for cancer research". Prof. Clevers comments on founding HUB and describes the Company´s mission saying “We set up a non-profit foundation called Hubrecht Organoid Technology (HUB), which holds my lab’s patents. In addition to carrying out research,
- [Curing genetic disease using patient-derived organoids](https://www.huborganoids.nl/news/curing-genetic-disease-in-patient-derived-organoids/) - Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest CRISPR technology works differently. The goal is to repair the error in the DNA without cutting it. Scientists from the research groups of Hans Clevers (Hubrecht Institute) and Jeffrey Beekman (UMC Utrecht) show for the
- [A message from our CEO on COVID-19](https://www.huborganoids.nl/news/a-message-from-our-ceo/) - Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. These are very difficult and challenging times for every organization. HUB greatly values its relationship with its customers and collaborators. We are committed to supporting you in these challenging times with minimal disruption to your
- [A new model developed on SARS-CoV-2 infected human intestinal organoids provides insights on gastrointestinal symptoms](https://www.huborganoids.nl/news/sars-cov-2-infects-cells-in-a-human-intestinal-organoid-model/) - Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have found that the coronavirus SARS-CoV-2, which causes COVID-19, can infect cells of the intestine and multiply there. Using state-of-the-art cell culture models of the human intestine, the researchers have successfully propagated the virus in vitro, and
- [HUB Organoids allow scientists to take a deeper look into gut hormones](https://www.huborganoids.nl/news/organoids-allowing-a-deep-look-into-the-gut-s-hormones/) - Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species of animals. Researchers from the Hubrecht Institute and Utrecht University developed an extensive toolbox to study human hormone-producing cells in tiny versions of the gut grown in the lab, called organoids. Organoids allowed them to
- [Novel organoid model that depicts the progression of high-grade serous ovarian cancer](https://www.huborganoids.nl/news/studying-ovarian-cancer-with-organoids/) - Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions of the female reproductive organs of the mouse. They found out that the cells of the oviduct, the equivalent of fallopian tubes in humans, are more prone to develop into tumors
- [Mini-Symposium: Organoids as Models of Infectious Disease](https://www.huborganoids.nl/news/mini-symposium-organoids-as-models-of-infectious-disease/) - HUB Organoids as models for precision medicine, in vitro diagnostics, and infectious disease. During this virtual mini-symposium co-hosted with our partner STEMCELL Technologies we discuss the development and characterization of organoid models, and how these are applied to precision medicine, diagnostics, and infectious disease.
- [HUB Organoids and Yamaha Motor Announce the Continuation of their Collaboration Combining Proprietary Technologies](https://www.huborganoids.nl/news/hub-and-yamaha-motor-announce-the-continuation-of-their-collaboration-combining-proprietary-technologies-hub-organoidstm-and-yamaha-cell-handler/) - April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today continuation of their collaboration to provide solutions that deepen our understanding of predictive diagnostics, with the overall goal to generate a predictive in vitro diagnostic (IVD) test. HUB and Yamaha Motor have announced the continuation of their collaboration to
- [Personalized Health Basel](https://www.huborganoids.nl/news/personalized-health-basel/) - Dr. Vries joins the monthly seminar series organized by the Personalized Health Basel (PHB) initiative. Personalized medicine holds great promise for the future of patient treatment, offering the opportunity to refine our understanding of risk/benefits of a new treatment and identify subsets of patients that are more likely to respond based on pharmacogenomic data.
- [HUB Organoids at Innovation Parade](https://www.huborganoids.nl/news/hub-at-innovation-parade/) - HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the Innovation Parade, an online event organized by the Embassy of the Kingdom of The Netherlands in Tokyo focused on innovative technologies by Dutch and Japanese partnerships. HUB and YAMAHA have started collaborating back in 2019 to increase accuracy, efficiency, and throughput of organoid research by automating organoid
- [Model inflammation in a dish](https://www.huborganoids.nl/news/model-inflammation-in-a-dish/) - Watch Dr. Sylvia Boj discussing how HUB Organoids accelerate the development of new therapeutics for inflammatory diseases. The lack of preclinical cellular models that recapitulate the human disease is a major setback in the study of non-oncogenic conditions with an inflammatory component.
- [Model human diseases and select treatment](https://www.huborganoids.nl/news/model-human-diseases-and-select-treatment/) - Our CEO Dr. Rob Vries discusses how HUB Organoids help modelling human disease and select best treatement options. Classic in vitro disease models are based on 2D immortalized cell lines that poorly recapitulate the morphology, physiology and genetic background of the original patient disease.
- [New paper: evaluate epithelial barrier function with HUB Organoids](https://www.huborganoids.nl/news/jove-epithelial-barrier-function-paper/) - Discover the development of a new model to assess drug safety, absorption, methabolism, transport, and permeability. Compromised intestinal barrier function has been associated with a number of intestinal and systemic diseases, including inflammatory bowel disease (IBD), obesity, metabolic disorders, and graft versus host disease.
- [HUB Organoids advance treatment for cystic fibrosis](https://www.huborganoids.nl/news/new-paper-hub-organoids-for-cystic-fibrosis/) - HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids™ advance treatment for Cystic Fibrosis. Promoting full-length CFTR protein production is a requisite step to address some of the remaining unmet medical need for Cystic Fibrosis (CF) patients carrying the nonsense allele G542X
- [STEMCELL Technologies and Hubrecht Organoid Technology to partner on non-oncology organoid drug screening services](https://www.huborganoids.nl/news/stemcell-technologies-and-hubrecht-organoid-technology-to-partner-on-non-oncology-organoid-drug-screening-services/) - VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. These services will help
- [Link revealed between HBV infection and liver cancer](https://www.huborganoids.nl/news/link-between-hbv-and-liver-cancer/) - HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events that drive liver cell transformation following Hepatitis B virus (HBV) infection have remained largely unclear, due to the absence of a relevant primary model system.
- [2021 Organoids are us](https://www.huborganoids.nl/news/2021-organoids-are-us/) - New online presentation available on the use of HUB Organoids™ as a revolutionary approach to disease modeling, drug screening, and patient stratification. Drug discovery and development should be performed using advanced preclinical models, directly derived from patient tissue, that can predict clinical response.
- [Industry-academic partnership to tackle tumor resistance](https://www.huborganoids.nl/news/new-persist-seq-program-launched/) - 2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in the field of cancer research which launches “PERSIST-SEQ”, a five-year public-private collaborative research program that aims to unravel drug resistance and develop smarter therapeutic strategies to treat cancer and prevent resistance. PERSIST-SEQ will
- [6th PREDiCT 3D Tissue Models](https://www.huborganoids.nl/news/6th-predict-3d-tissue-models/) - Meet our speaker Dr. Sylvia Boj discussing the next-gen models for complex disease modelling. Biopharma Pricing* - Register & Pay By Friday, February 11 & Save Up To $1,300
- [EUROTOX 2021 | Poster 553](https://www.huborganoids.nl/news/eurotox-2021-poster-553/) - Dr. Pourfarzad presents data on the use of HUB Organoids as advanced modes to investigate ADME and safety. Poster 553: HUB Organoids™ improve preclinical toxicology, metabolism, and pharmacokinetic studies for drug discovery and development.
- [2021 EUROTOX virtual congress](https://www.huborganoids.nl/news/2021-eurotox-virtual-congress/) - HUB presents two posters at the 2021 EUROTOX virtuals congress. Meet the scientists behind the data. Wondering whether you should consider in vivo vs in vitro models for your preclinical drug safety and ADME studies? Meet the authors of our two 2021 EUROTOX poster presentations to discover how HUB Organoids™ can help you
- [EUROTOX 2021 | Poster 391](https://www.huborganoids.nl/news/eurotox-2021-poster-391/) - Discover how to reduce costly animal experiments and obtain a quick indication of your drug safety with Merel Derksen. Poster 391: Intestinal organoids as in vitro model systems to assess safety and ADME properties of compounds.
- [Exclusive interview with Dr Carla Verissimo](https://www.huborganoids.nl/news/exclusive-interview-with-dr-carla-verissimo/) - Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview of the PREDiCT series. Exclusive Interview with Carla Verissimo, Head of Oncology II, HUB Organoid Technology.
- [Imagine reducing the time to identify a drug that shows results in the clinic to five years: this proof-of-concept study shows how](https://www.huborganoids.nl/news/imagine-reducing-the-time-to-identify-a-drug-that-shows-results-in-the-clinic-to-five-years-this-proof-of-concept-study-shows-how/) - Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do not respond to cetuximab, a recognized choice of antibody therapy. A new proof-of-concept study led by the SuppresSTEM European consortium discovers a bispecific antibody that prevents the onset of metastasis and sedates the

## Resources

- [De-risk your immuno-oncology drug development with HUB Organoids®](https://www.huborganoids.nl/resources/de-risk-your-immuno-oncology-drug-development/)
- [HUB Organoids in Preclinical Toxicology](https://www.huborganoids.nl/resources/hub-organoids-in-preclinical-toxicology/)
- [Accelerating oncology drug discovery with HUB Organoids®](https://www.huborganoids.nl/resources/white-paper-accelerating-oncology-drug-discovery-with-hub-organoids/)
- [Application of HUB Organoids in immuno-oncology drug development](https://www.huborganoids.nl/resources/application-of-hub-organoids/)
- [Transforming T cell therapy for solid tumors using patient-derived HUB Organoids®](https://www.huborganoids.nl/resources/transforming-t-cell-therapy-for-solid-tumors/)
- [Patient-Derived Organoids: A New Frontier in ADC Development](https://www.huborganoids.nl/resources/a-new-frontier-in-adc-development)
- [Discovery to Breakthrough Designation Therapy with HUB Organoids](https://www.huborganoids.nl/resources/drug-discovery-to-clinical-trials-in-five-years/)
- [Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer](https://www.huborganoids.nl/resources/patient-derived-organoids-predict-treatment-response-in-metastatic-colorectal-cancer) - Clin Cancer Res | 2025 Dec
- [Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond](https://www.huborganoids.nl/resources/accelerating-personalized-medicine) - npj Biomed. Innov. | 2026 Feb
- [How we supported our client in advancing biomarker discovery and translational ADC development](https://www.huborganoids.nl/resources/advancing-biomarker-discovery-and-translational-adc-development)
- [How organoid data guided our client in selecting a human-relevant animal model for preclinical toxicology studies](https://www.huborganoids.nl/resources/human-relevant-animal-model-for-preclinical-toxicology-studies)
- [How we helped our client anticipate on- and off-target toxicity using patient-derived organoids](https://www.huborganoids.nl/resources/anticipate-on-and-off-target-toxicity)
- [How we supported our client translate animal toxicity data to human-relevant insights and identify a therapeutic window](https://www.huborganoids.nl/resources/translate-animal-toxicity-data)
- [From Patient to Platform](https://www.huborganoids.nl/resources/from-patient-to-platform/)
- [Patient-derived Organoids: Transforming Infectious Disease Research and Drug Development](https://www.huborganoids.nl/resources/patient-derived-organoids-transforming-infectious-disease-research-and-drug-development/) - Dr. Sylvia Boj, Chief Scientific Officer
- [Patient-derived organoids as translational avatars for KRAS research](https://www.huborganoids.nl/resources/kras-research)
- [Regulators Embrace Organoids: Inside the FDA’s Shift Away from Animal Model](https://www.huborganoids.nl/resources/regulators-embrace-organoids-inside-the-fdas-shift-away-from-animal-model) - Last week, the FDA announced a transformative shift in drug development policy that monoclonal antibody (mAb) therapeutics may no longer require testing in animal models. Instead, the agency is endorsing next-generation approaches such as AI modelling and lab-grown human organoids designed to more accurately predict human responses and accelerate the path to clinical success.
- [Advancing immunotherapy for solid tumors with patient-derived organoids](https://www.huborganoids.nl/resources/advancing-immunotherapy-for-solid-tumors-with-patient-derived-organoids/)
- [How we enabled our client to bring an oncology clinical candidate to patients within five years](https://www.huborganoids.nl/resources/how-we-enabled-our-client-to-bring-an-oncology-clinical-candidate-to-patients-within-five-years)
- [How we enabled our client to assess efficacy and selectivity of a bispecific antibody using organoid-based co-cultures](https://www.huborganoids.nl/resources/how-we-enabled-our-client-to-assess-efficacy-and-selectivity-of-a-bispecific-antibody-using-organoid-based-co-cultures)
- [How we modelled human fibroblast-epithelial interactions with organoids to identify IBD targets](https://www.huborganoids.nl/resources/how-we-modelled-human-fibroblast-epithelial-interactions-with-organoids-to-identify-ibd-targets)
- [Ask the Expert: Inside the inFOCUS Assay for IBD Drug Discovery](https://www.huborganoids.nl/resources/inside-the-infocus-assay-for-ibd-drug-discovery) - In this "Ask the Expert" interview, Dr. Javier Frias Aldeguer, Senior Scientist at HUB Organoids shares insights into the inFOCUS assay—an innovative fibroblast-organoid co-culture model developed to explore the role of inflammatory fibroblasts in Inflammatory Bowel Disease (IBD).
- [Minimizing Oncology Drug Failure Rates Using Organoid Modeling and Multi-omic Data](https://www.huborganoids.nl/resources/minimizing-oncology-drug-failure-rates-using-organoid-modeling-and-multi-omic-data/) - Dr. Sylvia Boj, Chief Scientific Officer Daniella Patton, Principal Scientific Consultant, Genedata
- [Patient-Derived Airway Organoids for Modelling Rhinovirus Infection](https://www.huborganoids.nl/resources/patient-derived-airway-organoids-for-modelling-rhinovirus-infection/)
- [3D In-Vitro Fibroblast-Patient Derived Organoid Co-Culture: A High-Throughput Platform for Inflammatory Bowel Disease Drug Development](https://www.huborganoids.nl/resources/3d-in-vitro-fibroblast-patient-derived-organoid-co-culture-a-high-throughput-platform-for-inflammatory-bowel-disease-drug-development/)
- [Reconstructing tumor microenvironment with patient-derived organoids for derisking Immuno-Oncology therapies](https://www.huborganoids.nl/resources/reconstructing-tumor-microenvironment-with-patient-derived-organoids-for-derisking-immuno-oncology-therapies/)
- [The KRAS Conundrum: Challenges and strategies for targeted therapies in cancer](https://www.huborganoids.nl/resources/challenges-and-strategies-for-targeted-therapies-in-cancer/) - KRAS is a proto-oncogene that is crucial in regulating cell growth and division. Mutations in the KRAS gene are commonly found in various cancers, including colorectal pancreatic, and lung cancers.
- [Ask the Expert: How can patient-derived organoids accelerate KRAS drug development?](https://www.huborganoids.nl/resources/how-can-patient-derived-organoids-accelerate-kras-drug-development/) - RAS proteins have been considered undruggable for several reasons. First, they have a very smooth surface without well-defined binding pockets, making it difficult for small molecule inhibitors to bind tightly and precisely.
- [Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response](https://www.huborganoids.nl/resources/organoids-as-a-biomarker-for-personalized-treatment-in-metastatic-colorectal-cancer-drug-screen-optimization-and-correlation-with-patient-response/) - J Exp Clin Cancer Res | 2024 Feb
- [Mini-Organs, Major Breakthroughs: Accelerating Oncology Drug Development](https://www.huborganoids.nl/resources/mini-organs-major-breakthroughs-accelerating-oncology-drug-development/) - Dr. Sylvia Boj, Chief Scientific Officer
- [Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity](https://www.huborganoids.nl/resources/patient-derived-organoids-as-a-reliable-screening-platform-for-assessing-adc-efficacy-and-specificity/)
- [Resistant PDO models: Unraveling drug resistance mechanisms for discovering new drug targets](https://www.huborganoids.nl/resources/resistant-pdo-models-unraveling-drug-resistance-mechanisms-for-discovering-new-drug-targets/)
- [Patient-derived organoids: A pre-clinical model to assess infection and killing capacity of viral vectors for cancer therapy](https://www.huborganoids.nl/resources/patient-derived-organoids-a-pre-clinical-model-to-assess-infection-and-killing-capacity-of-viral-vectors-for-cancer-therapy/)
- [Miniaturizing patient-derived organoid screening assays for predictive drug testing](https://www.huborganoids.nl/resources/miniaturizing-patient-derived-organoid-screening-assays-for-predictive-drug-testing/)
- [Tumor organoid and immune cells co-cultures to study myeloid cells-targeting immunotherapy](https://www.huborganoids.nl/resources/tumor-organoid-and-immune-cells-co-cultures-to-study-myeloid-cells-targeting-immunotherapy/)
- [Mechanistic validation of MAIT cell engagers in HUB Patient-Derived Organoids (PDO) co-culture model](https://www.huborganoids.nl/resources/mechanistic-validation-of-mait-cell-engagers-in-hub-patient-derived-organoids-pdo-co-culture-model/)
- [A patient-derived organoid platform to assess the effectiveness of γδTCR cell therapy in solid tumors](https://www.huborganoids.nl/resources/a-patient-derived-organoid-platform-to-assess-the-effectiveness-of-γotcr-cell-therapy-in-solid-tumors/)
- [Tumor organoids](https://www.huborganoids.nl/resources/hub-tumor-organoid-models/)
- [Enhancing Drug Safety and ADME Assessment with Organoids](https://www.huborganoids.nl/resources/enhancing-drug-safety-and-adme-assessment-with-organoids/)
- [HUB Organoids as a Reliable Platform to Assess Gastrointestinal Toxicity](https://www.huborganoids.nl/resources/hub-organoids-as-a-reliable-platform-to-assess-gastrointestinal-toxicity/)
- [PDO Monolayer for Inflammatory Bowel Disease (IBD)](https://www.huborganoids.nl/resources/pdo-monolayer-for-inflammatory-bowel-disease/)
- [Decoding adult stem cells: exploring the hallmarks of stemness](https://www.huborganoids.nl/resources/decoding-adult-stem-cells/) - Mammalian organ systems face a constant barrage of internal and external stressors, leading to cellular attrition and functional decline. Maintaining tissue homeostasis in this dynamic environment requires a coordinated response from diverse populations of adult stem cells (ASCs). Recent years have witnessed a paradigm shift in our understanding of ASCs, revealing a remarkable heterogeneity in
- [A beginner’s guide to Inflammatory Bowel Diseases (IBD)](https://www.huborganoids.nl/resources/a-beginners-guide-to-inflammatory-bowel-diseases-ibd/) - Inflammatory Bowel Disease (IBD) is a complex condition that affects millions worldwide. Understanding its nuances is crucial for patients, caregivers, and those seeking to enhance their knowledge of gastrointestinal health. In this beginner's guide, we'll delve into the basics of IBD, its potential causes, and available treatment options.
- [Patient-derived Organoids: a powerful preclinical platform for de-risking immuno-oncology therapies](https://www.huborganoids.nl/resources/patient-derived-organoids-a-powerful-preclinical-platform-for-de-risking-immuno-oncology-therapies/)
- [Organoid monolayers: a patient-relevant platform to study intestinal barrier function, inflammatory bowel disease (IBD), and GI toxicity](https://www.huborganoids.nl/resources/organoid-monolayers-a-patient-relevant-platform-to-study-intestinal-barrier-function-inflammatory-bowel-disease-ibd-and-gi-toxicity/)
- [Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer](https://www.huborganoids.nl/resources/drug-repurposing-screen-on-patient-derived-organoids-identifies-therapy-induced-vulnerability-in-kras-mutant-colon-cancer/) - Cell Rep | April 2023
- [Human kidney patient-derived organoids are a promising tool for modeling drug-induced nephrotoxicity and for assessing preclinical toxicity of immunotherapy](https://www.huborganoids.nl/resources/human-kidney-patient-derived-organoids/)
- [10 years of breakthroughs in Organoid Technology: from adult stem cell discovery to changing patients’ lives](https://www.huborganoids.nl/resources/10-years-of-breakthroughs-in-organoid-technology/) - Dr. Robert Vries, CEO
- [Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules](https://www.huborganoids.nl/resources/intestinal-organoids-as-an-in-vitro-platform-to-characterize-disposition-metabolism-and-safety-profile-of-small-molecules/) - Eur J Pharm Sci | July 2023
- [Ask the Experts – organoid & immune cell co-cultures for immunotherapy](https://www.huborganoids.nl/resources/ask-the-experts-organoid-immune-cell-co-cultures-for-immunotherapy/) - In this post of our "Ask the Experts" series, we provide comprehensive answers to frequently asked questions regarding the practical applications of HUB Organoid-based immune cell co-cultures in the field of immunotherapy development. Our responses cover a range of pertinent topics, including our co-culture platform for T cell testing, the immuno-oncology biobank we utilize, and
- [A Patient-Derived Organoid Platform to Investigate Gastrointestinal and Liver Toxicities](https://www.huborganoids.nl/resources/a-patient-derived-organoid-platform-to-investigate-gastrointestinal-and-liver-toxicities/) - Dr. Sylvia F. Boj, Chief Scientific Officer
- [Patient-derived organoids: an emerging platform to de-risk immunotherapy development](https://www.huborganoids.nl/resources/de-risk-immunotherapy-development/) - Dr. Sylvia F. Boj, Chief Scientific Officer
- [Optimization of screening conditions using patient-derived organoids for diagnostic purposes](https://www.huborganoids.nl/resources/patient-derived-organoids-for-diagnostic-purposes/)
- [Patient in the lab: Down-scaling patient-derived organoid screening for diagnostic purposes](https://www.huborganoids.nl/resources/patient-in-the-lab-down-scaling-patient-derived-organoid-screening-for-diagnostic-purposes/)
- [Developing a patient-derived organoid biobank, suitable for large-scale drug screenings](https://www.huborganoids.nl/resources/developing-a-patient-derived-organoid-biobank/)
- [Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy](https://www.huborganoids.nl/resources/autologous-organoids-and-t-cell-co-cultures-2/)
- [Tumour organoid and T-cell co-culture assay to evaluate CAR T-cell cytotoxicity](https://www.huborganoids.nl/resources/tumour-organoid-and-t-cell-co-culture-assay/)
- [Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies](https://www.huborganoids.nl/resources/organoid-co-cultures-with-autologous-t-cells-2/)
- [Tumour organoid and T cell co-cultures to evaluate CAR-T cell cytotoxicity](https://www.huborganoids.nl/resources/evaluate-car-t-cell-cytotoxicity/)
- [Recent advancements in patient-derived organoid technology and their impact on drug development](https://www.huborganoids.nl/resources/patient-derived-organoid-technology/) - Dr. Sylvia F. Boj, Chief Scientific Officer
- [PDO Screen – Patient-derived Organoids meet Cancer Modeling](https://www.huborganoids.nl/resources/pdo-screen-patient-derived-organoids-meet-cancer-modeling/) - Discover how patient-derived organoids can revolutionize oncology research by enabling accurate modeling of tumor biology and predicting patient response to treatment. We have come a long way in treating cancer. From surgeries, radiations, and injecting systemic drugs, to tailoring therapies that delicately disintegrate tumors. Despite advances in the field, there is still a considerable distance
- [Ask the experts - organoids for viral infection studies](https://www.huborganoids.nl/resources/ask-the-experts-organoids-for-viral-infection-studies/) - HUB and STEMCELL Technologies experts gathered virtually for a mini-symposium to discuss the development and characterization of organoids, how they are applied to studying organ development and disease, and the latest progess in understanding infectious diseases like COVID-19. We asked the audience to submit their questions during the event and here is a chance to
- [Ask the experts - organoids for oncology studies](https://www.huborganoids.nl/resources/ask-the-experts-organoids-for-oncology-studies/) - In the first post from our "Ask the experts" series we have answered the most commonly asked questions around the applications of HUB Organoids™ to viral infection studies. Here we discuss how they are contributing to our understanding of cancer biology and revolutionizing oncology drug development Drs. Robert Vries, Sylvia Boj from HUB and Dr.
- [Ask the experts - organoids in drug development](https://www.huborganoids.nl/resources/ask-the-experts-organoids-in-drug-development/) - After discussing HUB Organoids™ applications to viral and oncology studies, Drs Rob Vries, CEO and Sylvia Boj CSO from HUB review together with Dr Ryan Conder from our partner STEMCELL Technologies how organoids are being applied to drug development. ORGANOIDS IN DRUG DEVELOPMENT How are organoids affecting the landscape of clinical and preclinical drug development?
- [Ask the experts - organoids as model systems](https://www.huborganoids.nl/resources/ask-the-experts-organoids-as-model-systems/) - In this last episode of our "Ask the experts" series we explore the difference between HUB Organoids™ and iPSCs-derived organoids and discuss optimal applications of organoids compared to other preclinical models such as 2D cell lines and animal models. Drs. Robert Vries, Sylvia Boj from HUB and Dr. Ryan Conder from our partner STEMCELL Technologies
- [Do you need a license to work with HUB Organoid® Technology?](https://www.huborganoids.nl/resources/do-you-need-a-license-to-work-with-hub-organoid-technology/) - Explore HUB’s license offerings and how they apply to your organoid research projects HUB’s proprietary technology enables the production of mini-organs in a dish from patient-derived tissue . As the global leader in the field of adult stem cell-derived organoids, one of HUB’s missions is to increase the global accessibility of HUB Organoid Technology. HUB
- [Forecasting a champion: How HUB Organoids® can speed up the drug development timeline to about five years](https://www.huborganoids.nl/resources/forecasting-a-champion-how-hub-organoids-can-speed-up-the-drug-development-timeline-to-about-five-years/) - Learn why you should invest in patient-derived HUB Organoids® for your drug screening program Drug discovery is like horse betting, except it takes 12 years to reveal the race's outcome. When the race is this long, an array of evidence-based estimations should be the go-to strategy to pick a winning candidate. Betting on the right
- [Challenges in preclinical modeling of cancer immunity](https://www.huborganoids.nl/resources/challenges-in-preclinical-modeling-of-cancer-immunity/) - Learn how to select the right model for your immunotherapy development Over the past decade, immunotherapy has revolutionized oncology. From ipilimumab improving survival by delaying disease progression in advanced melanoma patients to the recent FDA approval of nivolumab for lung cancer. Despite their success and long-term durable responses in previously untreatable populations, immunotherapies are currently
- [The FDA Modernization Act 2.0: A patient-centric paradigm shift in drug development](https://www.huborganoids.nl/resources/the-fda-modernization-act-2-0-a-patient-centric-paradigm-shift-in-drug-development/) - Explore what the new legislative bill means for the future of organoid technology in drug development The use of animals to test human pharmaceuticals dates back to 1937 when an untested formulation of a sulfa antibiotic resulted in the deaths of 100s of adults and children in the United States. Popularly known as the “1937
- [MIMETAS Expands Adult Stem Cell Organoid License to All Organs](https://www.huborganoids.nl/resources/mimetas-expands-adult-stem-cell-organoid-license-to-all-organs/) - Leiden, The Netherlands, May 3, 2022 – MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today that it has expanded its license to the HUB Organoid Technology to include all organs. The license covers organoid technology developed by Professor Hans Clevers, a pioneer in adult stem cells. “This is a crucial addition to our
- [New partner: Yamaha Motor](https://www.huborganoids.nl/resources/new-partner-yamaha-motor/) - February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their collaboration to provide solutions that deepen our understanding in predictive diagnostic of patients.
- [New partner: CrownBio](https://www.huborganoids.nl/resources/new-partner-crownbio/) - March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation, the parent company, of Crown Bioscience, entered into a strategic partnership to provide preclinical oncology drug development and validation services using HUB Organoid Technology. As part of the agreement CrownBio, a wholly–owned subsidiary of JSR Corporation will expand its European presence by opening a
- [HUB PDOs now at CrownBio](https://www.huborganoids.nl/resources/hub-pdos-now-at-crownbio/) - San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology (HUB) patient-derived organoids (PDO). This marks a significant milestone in the development of CrownBio’s innovative organoid platform and the first, large-scale commercial availability of HUB PDO for oncology drug discovery services.
- [Epistem license HUB Technology](https://www.huborganoids.nl/resources/epistem-license-hub-technology/) - Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification
- [Organoids-on-a-chip](https://www.huborganoids.nl/resources/organoids-on-a-chip/) - Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to market organoid models on a chip. The agreement includes a license to MIMETAS to market HUB Organoids™ in an assay ready format, as well as a collaborative effort to develop disease-specific models.
- [PDX organoids in drug development](https://www.huborganoids.nl/resources/pdx-organoids-in-drug-development/) - San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery.
- [HUB on Financial Times](https://www.huborganoids.nl/resources/hub-on-financial-times/) - On December 10, 2019 the Financial Times featured HUB Organoids™ in an article titled “Organoid innovation offers potential for cancer research".
- [Organoids for genetic disorders](https://www.huborganoids.nl/resources/organoids-for-genetic-disorders/) - Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest CRISPR technology works differently. The goal is to repair the error in the DNA without cutting it. Scientists from the research groups of Hans Clevers (Hubrecht Institute) and Jeffrey Beekman (UMC Utrecht) show for the
- [A message from our CEO](https://www.huborganoids.nl/resources/a-message-from-our-ceo/) - Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. These are very difficult and challenging times for every organization.
- [SARS-CoV-2 infects gut cells](https://www.huborganoids.nl/resources/sars-cov-2-infects-gut-cells/) - Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have found that the coronavirus SARS-CoV-2, which causes COVID-19, can infect cells of the intestine and multiply there. Using state-of-the-art cell culture models of the human intestine, the researchers have successfully propagated the virus in vitro, and
- [Understanding gut’s hormones](https://www.huborganoids.nl/resources/understanding-guts-hormones/) - Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species of animals. Researchers from the Hubrecht Institute and Utrecht University developed an extensive toolbox to study human hormone-producing cells in tiny versions of the gut grown in the lab, called organoids. Organoids allowed them to
- [Ovarian cancer organoids](https://www.huborganoids.nl/resources/ovarian-cancer-organoids/) - Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions of the female reproductive organs of the mouse. They found out that the cells of the oviduct, the equivalent of fallopian tubes in humans, are more prone to develop into tumors
- [HUB and Yamaha for IVD](https://www.huborganoids.nl/resources/hub-and-yamaha-for-ivd/) - April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today continuation of their collaboration to provide solutions that deepen our understanding of predictive diagnostics, with the overall goal to generate a predictive in vitro diagnostic (IVD) test. HUB and Yamaha Motor have announced the continuation of their collaboration to
- [HUB at Innovation Parade](https://www.huborganoids.nl/resources/hub-at-innovation-parade/) - HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the Innovation Parade, an online event organized by the Embassy of the Kingdom of The Netherlands in Tokyo focused on innovative technologies by Dutch and Japanese partnerships.
- [New service partnership](https://www.huborganoids.nl/resources/new-service-partnership/) - VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. These services will help
- [New PERSIST-SEQ program launched](https://www.huborganoids.nl/resources/new-persist-seq-program-launched/) - 2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in the field of cancer research which launches “PERSIST-SEQ”, a five-year public-private collaborative research program that aims to unravel drug resistance and develop smarter therapeutic strategies to treat cancer and prevent resistance. PERSIST-SEQ will
- [Exclusive interview with Dr Carla Verissimo](https://www.huborganoids.nl/resources/exclusive-interview-with-dr-carla-verissimo/) - Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview of the PREDiCT series. Exclusive Interview with Carla Verissimo, Head of Oncology II, HUB Organoid Technology.
- [First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer](https://www.huborganoids.nl/resources/first-clinical-candidate-developed-using-hub-organoids-and-high-content-screening-targets-cancer-stem-cells-in-solid-tumors-published-in-nature-cancer/) - San Diego, California, April 28, 2022 – Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer. The study was the result of work
- [Imagine reducing the time to identify a drug that shows results in the clinic to five years: this proof-of-concept study shows it is possible now](https://www.huborganoids.nl/resources/imagine-reducing-the-time-to-identify-a-drug-that-shows-results-in-the-clinic-to-five-years-this-proof-of-concept-study-shows-it-is-possible-now/) - The study identifies the first clinical candidate developed using HUB Organoids® and high-content screening that inhibits tumor growth and metastasis in colorectal cancer.
- [Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver](https://www.huborganoids.nl/resources/long-term-culture-of-genome-stable-bipotent-stem-cells-from-adult-human-liver/) - Cell | January 2015
- [Tissue-specific mutation accumulation in human adult stem cells during life](https://www.huborganoids.nl/resources/tissue-specific-mutation-accumulation-in-human-adult-stem-cells-during-life/) - Nature | October 2016
- [Establishment of Pancreatic Organoids from Normal Tissue and Tumors](https://www.huborganoids.nl/resources/establishment-of-pancreatic-organoids-from-normal-tissue-and-tumors/) - STAR Protocols, Cell | December 2020
- [Pancreatic cancer organoids recapitulate disease and allow personalized drug screening](https://www.huborganoids.nl/resources/pancreatic-cancer-organoids-recapitulate-disease-and-allow-personalized-drug-screening/) - Proc Natl Acad Sci USA | December 2019
- [Organoid Models of Human and Mouse Ductal Pancreatic Cancer](https://www.huborganoids.nl/resources/organoid-models-of-human-and-mouse-ductal-pancreatic-cancer/) - Cell | January 2015
- [Patient-derived organoids as a predictive biomarker for treatment response in cancer patients](https://www.huborganoids.nl/resources/patient-derived-organoids-as-a-predictive-biomarker-for-treatment-response-in-cancer-patients/) - NPJ Precis Oncol | April 2021
- [Long-term expanding human airway organoids for disease modeling](https://www.huborganoids.nl/resources/long-term-expanding-human-airway-organoids-for-disease-modeling/) - EMBO J | February 2019
- [Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers for Modeling Epithelial Barrier](https://www.huborganoids.nl/resources/molecular-and-functional-characterization-of-human-intestinal-organoids-and-monolayers-for-modeling-epithelial-barrier/) - Inflamm Bowel Dis | Nov 2022
- [Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors](https://www.huborganoids.nl/resources/functional-patient-derived-organoid-screenings-identify-mcla-158-as-a-therapeutic-egfr-x-lgr5-bispecific-antibody-with-efficacy-in-epithelial-tumors/) - Nat Cancer | April 2022
- [Sequential cancer mutations in cultured human intestinal stem cells](https://www.huborganoids.nl/resources/sequential-cancer-mutations-in-cultured-human-intestinal-stem-cells/) - Nature | May 2015
- [Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis](https://www.huborganoids.nl/resources/rectal-organoids-enable-personalized-treatment-of-cystic-fibrosis/) - Cell Rep | February 2019
- [Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation](https://www.huborganoids.nl/resources/lumacaftor-ivacaftor-in-people-with-cystic-fibrosis-with-an-a455e-cftr-mutation/) - J Cyst Fibros | Sep 2021 | Clinical trial
- [G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect](https://www.huborganoids.nl/resources/g970r-cftr-mutation-c-2908gc-results-predominantly-in-a-splicing-defect/) - Clin Transl Sci | March 2021
- [Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids](https://www.huborganoids.nl/resources/long-term-culture-genetic-manipulation-and-xenotransplantation-of-human-normal-and-breast-cancer-organoids/) - Nat Protoc | April 2021
- [A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity](https://www.huborganoids.nl/resources/a-living-biobank-of-breast-cancer-organoids-captures-disease-heterogeneity/) - Cell | Jan 2018
- [Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening](https://www.huborganoids.nl/resources/targeting-mutant-ras-in-patient-derived-colorectal-cancer-organoids-by-combinatorial-drug-screening/) - eLife | Nov 2016
- [Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium](https://www.huborganoids.nl/resources/long-term-expansion-of-epithelial-organoids-from-human-colon-adenoma-adenocarcinoma-and-barretts-epithelium/) - Gastroenterology | Nov 2011
- [Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche](https://www.huborganoids.nl/resources/single-lgr5-stem-cells-build-crypt-villus-structures-in-vitro-without-a-mesenchymal-niche/) - Nature | May 2009
- [Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients](https://www.huborganoids.nl/resources/prospective-derivation-of-a-living-organoid-biobank-of-colorectal-cancer-patients/) - Cell | May 2015
- [Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal](https://www.huborganoids.nl/resources/test-epithelial-barrier-function/) - J Vis Exp | July 2021
- [Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma](https://www.huborganoids.nl/resources/link-revealed-between-hbv-infection-and-liver-cancer/) - eLife | July 2021
- [HUB Organoids as models for precision medicine, in vitro diagnostics, and infectious disease](https://www.huborganoids.nl/resources/organoids-for-infectious-disease/) - Robert Vries, CEO & Sylvia Boj, CSO HUB Organoids; Ryan Conder, STEMCELL Technologies
- [Modelling human inflammation "in a dish"](https://www.huborganoids.nl/resources/model-inflammation-in-a-dish/) - Sylvia Boj, CSO HUB Organoids
- [HUB Organoids as unique tools for personalized medicine](https://www.huborganoids.nl/resources/personalized-health-basel/) - Robert Vries, CEO HUB Organoids
- [Understanding mechanism of disease and identifying therapeutic interventions with HUB Organoids](https://www.huborganoids.nl/resources/understanding-mechanism-of-disease/) - Robert Vries, CEO HUB Organoids
- [Patient in the lab®: downscaling patient-derived organoid screening](https://www.huborganoids.nl/resources/patient-in-the-lab-downscaling-patient-derived-organoid-screening/) - René Overmeer, Head of Assay Development and Automation HUB Organoids
- [Model human disease and identify predictive biomarkers of response](https://www.huborganoids.nl/resources/2021-organoids-are-us/) - Robert Vries, CEO HUB Organoids
- [HUB Organoids in cystic fibrosis](https://www.huborganoids.nl/resources/cystic-fibrosis-organoid-models/)
- [License HUB Organoid Technology](https://www.huborganoids.nl/resources/license-hub-organoid-technology/)
- [Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids](https://www.huborganoids.nl/resources/cf-models-for-drug-development/) - J Cyst Fibros | May 2021
- [Potential of liver organoids in preclinical evaluation of toxicity, safety and mode of action](https://www.huborganoids.nl/resources/eurotox-2021-poster-553/)
- [HUB Organoids applications to drug safety and ADME evaluation](https://www.huborganoids.nl/resources/eurotox-2021-poster-391/)
- [Application of HUB Organoids® to Immunotherapy development](https://www.huborganoids.nl/resources/application-of-hub-organoids-to-immunotherapy-development/)
- [Patient-derived organoids predict clinical response: a patient in the lab](https://www.huborganoids.nl/resources/patient-derived-organoids-predict-clinical-response-a-patient-in-the-lab/)
- [Patient in the lab: predicting clinical responses using patient-derived organoid screening](https://www.huborganoids.nl/resources/patient-in-the-lab-predicting-clinical-responses-using-patient-derived-organoid-screening/)
- [Patient-derived organoids predict clinical response: a patient in the lab](https://www.huborganoids.nl/resources/elrig-2022-poster-a-patient-in-the-lab/)
- [Development of a medium-to-high throughput organoid and bacteria co-culture platform for the assessment of host-pathogen interaction](https://www.huborganoids.nl/resources/development-of-a-medium-to-high-throughput-organoid-and-bacteria-co-culture-platform-for-the-assessment-of-host-pathogen-interaction/)
- [Patient-derived organoids as a model for treatment diagnosis in Cystic Fibrosis – combinatory treatment with read-through agent, correctors and potentiator on rare mutations](https://www.huborganoids.nl/resources/patient-derived-organoids-poster/)
- [Human liver patient-derived HUB Organoids as a promising tool to study drug-induced liver injury and drug metabolism for improved preclinical toxicology assessment](https://www.huborganoids.nl/resources/human-liver-patient-derived-hub-organoids/)
- [Patient-derived organoids as a relevant tool for preclinical IBD research and drug development](https://www.huborganoids.nl/resources/preclinical-ibd-research-and-drug-development/)
- [Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy](https://www.huborganoids.nl/resources/powerful-personalized-platform-for-immunotherapy/)
- [Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy](https://www.huborganoids.nl/resources/autologous-organoids-and-t-cell-co-cultures/)
- [Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies](https://www.huborganoids.nl/resources/organoid-co-cultures-with-autologous-t-cells/)
- [Developing a patient-derived bladder cancer organoid biobank suitable for large-scale drug screenings](https://www.huborganoids.nl/resources/developing-a-patient-derived-bladder-cancer-organoid-biobank/)

## News Categories

- [News and Insights](https://www.huborganoids.nl/news_category/news-and-insights/)
- [Meet Us](https://www.huborganoids.nl/news_category/meet-us/)

## Resource Categories

- [news and insights](https://www.huborganoids.nl/resource_category/news-and-insights/)
- [fact sheet](https://www.huborganoids.nl/resource_category/fact-sheets/)
- [white papers](https://www.huborganoids.nl/resource_category/white-papers/)
- [posters](https://www.huborganoids.nl/resource_category/posters/)
- [publications](https://www.huborganoids.nl/resource_category/publications/)
- [info sheet](https://www.huborganoids.nl/resource_category/info-sheets/)
- [case study](https://www.huborganoids.nl/resource_category/case-study/)
- [ON-DEMAND PRESENTATION](https://www.huborganoids.nl/resource_category/on-demand-presentation/)
- [organoid screening](https://www.huborganoids.nl/resource_category/organoid-screening/)
- [inflammatory disease](https://www.huborganoids.nl/resource_category/inflammatory-disease/)
- [personalised medicine](https://www.huborganoids.nl/resource_category/personalised-medicine/)
- [infectious disease](https://www.huborganoids.nl/resource_category/infectious-disease/)
- [cystic fibrosis](https://www.huborganoids.nl/resource_category/cystic-fibrosis-publication/)
- [immuno-oncology](https://www.huborganoids.nl/resource_category/immunooncology-posters/)
- [inflammatory bowel disease](https://www.huborganoids.nl/resource_category/inflammatory-bowel-disease-posters/)
- [oncology](https://www.huborganoids.nl/resource_category/oncology-posters/)
- [toxicology](https://www.huborganoids.nl/resource_category/toxicology-posters/)
- [cystic fibrosis](https://www.huborganoids.nl/resource_category/cystic-fibrosis-posters/)
- [oncology](https://www.huborganoids.nl/resource_category/oncology-white-paper/)
- [oncology](https://www.huborganoids.nl/resource_category/oncology-case-study/)
- [immuno-oncology](https://www.huborganoids.nl/resource_category/immunooncology-info-sheet/)
- [immuno-oncology](https://www.huborganoids.nl/resource_category/immunooncology-fact-sheet/)
- [organoid technology](https://www.huborganoids.nl/resource_category/organoid-technology-fact-sheet/)
- [oncology](https://www.huborganoids.nl/resource_category/oncology-factsheet/)
- [cystic fibrosis](https://www.huborganoids.nl/resource_category/cystic-fibrosis-fact-sheet/)
- [infectious disease](https://www.huborganoids.nl/resource_category/infectious-disease-publication/)
- [inflammatory bowel disease](https://www.huborganoids.nl/resource_category/inflammatory-bowel-disease-publication/)
- [oncology](https://www.huborganoids.nl/resource_category/oncology-publication/)
- [organoid technology](https://www.huborganoids.nl/resource_category/organoid-technology-publication/)
- [Blog](https://www.huborganoids.nl/resource_category/blog/)
- [Organoid Technology](https://www.huborganoids.nl/resource_category/organoid-technology/)
- [immuno-oncology](https://www.huborganoids.nl/resource_category/immuno-oncology/)
- [Toxicology](https://www.huborganoids.nl/resource_category/toxicology/)
- [toxicology](https://www.huborganoids.nl/resource_category/toxicology-publications/) - toxicology
- [inflammatory bowel disease](https://www.huborganoids.nl/resource_category/inflammatory-bowel-disease/)
- [toxicology](https://www.huborganoids.nl/resource_category/toxicology-info-sheets/) - toxicology
- [Oncology](https://www.huborganoids.nl/resource_category/oncology/) - Oncology
- [INFECTION DISEASE](https://www.huborganoids.nl/resource_category/infection-disease/)
- [inflammatory bowel disease](https://www.huborganoids.nl/resource_category/inflammatory-bowel-disease-case-study/)
- [Organoid Technology](https://www.huborganoids.nl/resource_category/organoid-technology-info-sheets/)
- [Toxicology](https://www.huborganoids.nl/resource_category/toxicology-case-study/)